US-based Sherpa Clinical Packaging has completed its operational shift to a new GMP clinical packaging and distribution facility in San Diego, California.
The latest 37,500ft² facility has improved capabilities and strict cold chain management infrastructure.
The firm stated that the expansion was required to support its growing demand for phase two and phase three clinical studies, as well as better serve its new and old clients.
Sherpa Clinical Packaging president Mark Paiz said: "The new Sherpa facility will help sustain the continued growth of our company.
"Sherpa’s mission is to be the customer service leader in the clinical trial materials management business and we offer each client the trusting and reliable relationship that people vested in clinical trials seek."
The new facility offers space for primary and secondary clinical labelling and packaging, GMP storage for refrigerated (2°C to 8°C), frozen (-20°C, -80°C and LN2), controlled room temperature (20°C to 25°C) and temperature-controlled shipping dispatch.
The GMP clinical packaging and distribution facility includes an ISO 8 clean room that is required for primary packaging of solid dose products.
Sherpa Clinical Packaging also now specialises in cold form and thermoform blistering, API storage and blister strip carding.
The company stated that it has been successful in moving its operations to a new facility without any disturbance or interruption in its business.
Sherpa Clinical Packaging opened its CGMP production facility in San Diego in 2011.